fotagliptin (SAL067) / Shenzhen Salubris - LARVOL DELTA

Fotagliptin add-on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. (PubMed, Diabetes Obes Metab) - "In patients with T2D who experienced inadequate glycaemic control with metformin, fotagliptin achieved a superior and clinically meaningful improvement in glycaemic control compared with placebo."

Journal • P3 data • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

RI: The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P1 trial • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial. (PubMed, BMC Med) - P3 | "In summary, the study demonstrated improvement in glycemic control and a favorable safety profile for fotagliptin in treatment-naive patients with T2DM."

Clinical • Journal • Monotherapy • P3 data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin (clinicaltrials.gov) - P3 | N=408 | Completed | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus